<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/52AF26DF-D9A2-4A76-881B-2C421B622C30"><gtr:id>52AF26DF-D9A2-4A76-881B-2C421B622C30</gtr:id><gtr:name>Heidelberg University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A19E252-D0A6-407D-8633-610CD5122E4A"><gtr:id>7A19E252-D0A6-407D-8633-610CD5122E4A</gtr:id><gtr:name>UCL School of Life and Medical Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/52AF26DF-D9A2-4A76-881B-2C421B622C30"><gtr:id>52AF26DF-D9A2-4A76-881B-2C421B622C30</gtr:id><gtr:name>Heidelberg University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A19E252-D0A6-407D-8633-610CD5122E4A"><gtr:id>7A19E252-D0A6-407D-8633-610CD5122E4A</gtr:id><gtr:name>UCL School of Life and Medical Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F9FE21A-89BA-4B3E-8322-4BB5F7319B17"><gtr:id>3F9FE21A-89BA-4B3E-8322-4BB5F7319B17</gtr:id><gtr:firstName>Kenneth</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4016170F-07A0-4CB1-A324-206E3FB413B8"><gtr:id>4016170F-07A0-4CB1-A324-206E3FB413B8</gtr:id><gtr:firstName>Harold</gtr:firstName><gtr:otherNames>George</gtr:otherNames><gtr:surname>Parkes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800954"><gtr:id>C0CFFB1B-BE7C-4747-9C51-4D14951A6518</gtr:id><gtr:title>To develop therapies and a strategy for their translation to treat early lesions in multiple sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800954</gtr:grantReference><gtr:abstractText>We aim to develop a medicine to treat patients with multiple sclerosis (MS) so that permanent damage to their brain is diminished, or perhaps even prevented. MS causes inflammatory lesions within the brain and this can irreversibly damage the delicate brain tissue, either causing the nerve fibres to lose their insulating layer of myelin, or killing the nerve fibres. This damage causes the devastating symptoms, including blindness, paralysis and numbness. The reason inflammation damages the brain is not known but our evidence is that a lack of oxygen may be part of the problem. The inflamed brain may use so much oxygen that it cannot be provided fast enough by the blood. To find out, we propose to induce a small inflammatory lesion that mimics the MS lesion in part of the rat spinal cord, under general anaesthesia. The lesion is so small, and carefully placed, that the rats show no symptoms at all, but the lesion is sufficiently large to be able to see it clearly under the microscope. Rats with the lesion will be treated with one of a number of different therapies designed to reduce the damage caused by the inflammation. The efficacy of the therapy will be assessed microscopically by comparing the size and nature of the treated and untreated lesions. The treatments are based on a belief that improving oxygenation of the inflamed tissue will help it to survive the harsh conditions of the inflammation. Some treatments simply involve increasing the oxygen supply in the breathing air, while others are designed to increase the delivery of oxygen to the brain by treating the blood vessels. Other treatments attempt to protect the inflamed tissue from damaging events initiated by the shortage of oxygen. One important goal is to obtain information about the properties of the lesion using a brain scanner, as used in hospitals. The reason is that if the properties of the experimental lesion are known, brain scanning can be used to distinguish those patients with similar lesions, and then it will be possible to apply the effective therapies to the particular patients anticipated to benefit from them. At present the particular type of lesion can only be detected by microscopy, either after death, or after taking a piece of brain tissue out during an operation. If the research is successful it will result in a new and effective therapy to prevent disability in MS.</gtr:abstractText><gtr:technicalSummary>Our goal is to develop a rational therapy for neuroprotection of the early or hypoxia-like lesions in multiple sclerosis. Our hypothesis is that the lipopolysaccharide (LPS) lesion in the rat is a valid model of such MS lesions, and that it can therefore be used to understand the pathogenesis of the MS lesion, and as a test bed to develop the first available therapy for neuroprotection in this type of MS lesion. We also hypothesise that the lesion is, unexpectedly, primarily caused by true tissue hypoxia (low oxygen concentration, not ischaemia), and this interpretation is clearly supported by new findings in our laboratory. This novel insight will guide our therapeutic strategy, which is based on a belief that the pathology is due to an underlying energy insufficiency. The insufficiency is believed due partly to nitric oxide-mediated mitochondrial inhibition, but also, and perhaps more importantly, to lack of sufficient oxygen for normal mitochondrial function. We will also use our new ability to perform high resolution MRI to obtain the imaging ?signature? of the LPS lesion so that patients with similar lesions can be distinguished during life: at present the lesions can only be distinguished histologically. The overarching strategy is then to apply the novel therapies to the particular subset of MS patients anticipated to benefit from them. The seamless translation of therapies to the clinic will be facilitated by the membership of the PI within the newly-funded MS Clinical Trials Unit located within the host department. 

Rats will have LPS lesions induced within their spinal cord and then they will receive treatments designed either to explore the mechanisms responsible for the demyelination and axonal loss that characterise the lesion, or to explore whether the pathology can be alleviated or prevented. The treatments will be based on our hypothesis regarding energy insufficiency, and will explore a) oxygen therapy, including breathing modified atmospheres and modifying blood flow, b) microglial inhibition using agents such as minocycline, c) therapies based on the partial inhibition of sodium channels, or of the sodium/calcium exchanger, d) the amelioration of glutamate toxicity, e) scavenging oxygen and nitrogen free radicals and promoting the decomposition of peroxynitrite, and f) the potential role of factors normally associated with blood coagulation. The effects of the different treatments on the size of the LPS lesion, and the magnitude of demyelination and axonal degeneration, will be determined using a range of standard histological techniques.</gtr:technicalSummary><gtr:fund><gtr:end>2012-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>711991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Mitochondrial Research Group Newcastle</gtr:department><gtr:description>Newcastle University</gtr:description><gtr:id>B7F51C81-E93E-4456-9154-34C6A374169A</gtr:id><gtr:impact>Pupblication:-
D.J. Mahad, G. Campbell, I. Ziabreva, F. Laulund, J. Murphy, A.K. Reeve, L. Greaves, K.J. Smith, D.M. Turnbull
Detection of cytochrome c oxidase activity and mitochondrial proteins in single cells. J. Neurosci. Meth. 2009;184:310-319</gtr:impact><gtr:partnerContribution>The collaboration has introduced an ability to study mitochondrial function by histological methods, which complements our confocal ability to study their function in vivo.</gtr:partnerContribution><gtr:piContribution>We supply the experimental tissue upon which the examination of mitochondrial function is made.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heidelberg University Hospital</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>Diem Heidelberg</gtr:description><gtr:id>C89CC59E-D099-43BE-B68F-8E033D1FF78F</gtr:id><gtr:impact>Publication about to be submitted to a high impact journal</gtr:impact><gtr:partnerContribution>They have suppied the tissue</gtr:partnerContribution><gtr:piContribution>We have assessed tissue from a model of MS for evidence of hypoxia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neuroscience and Psychology</gtr:department><gtr:description>Linington Glasgow</gtr:description><gtr:id>3834F479-6A60-4F54-9589-207C2F03212F</gtr:id><gtr:impact>High impact publication about to be submitted</gtr:impact><gtr:partnerContribution>Supply of materials to induce the model</gtr:partnerContribution><gtr:piContribution>Development and characterisation of a new model of MS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Neurology</gtr:department><gtr:description>Golay MRI</gtr:description><gtr:id>2AF2CE31-C812-4624-A1DE-5F94DB8679FB</gtr:id><gtr:impact>Two grant applications to the MRC - not funded</gtr:impact><gtr:partnerContribution>Expertise in MRI</gtr:partnerContribution><gtr:piContribution>Supply of experimental lesions for MRI imaging</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCL School of Life and Medical Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bloomsbury Institute of Intensive Care Medicine</gtr:department><gtr:description>Singer UCL</gtr:description><gtr:id>DC96B2F2-3238-4B09-A386-FD4B64600CAB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Expertise on hypoxia and blood flow in experimental lesions</gtr:partnerContribution><gtr:piContribution>Expertise on hypoxia and blood flow in experimental lesions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>Murphy Cambridge</gtr:description><gtr:id>0FB96EB9-E33F-44A0-B64A-9A2A99A35EEE</gtr:id><gtr:impact>Paper is about to be submitted (next week) to a high impact journal</gtr:impact><gtr:partnerContribution>He has suppied the drug and expertise</gtr:partnerContribution><gtr:piContribution>We have explored the value of a potential neuroprotective drug in models of MS</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Center for Brain Research</gtr:department><gtr:description>Medical University of Vienna</gtr:description><gtr:id>D1C184D7-00DF-45F5-8202-07E398F7B787</gtr:id><gtr:impact>C. Marik, P.A. Felts, J. Bauer, H. Lassmann, K.J. Smith
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain, 2007 130:2800-2815. PM: 17956913; PMC2981817

R. Sharma, M.T. Fischer, J. Bauer, K.J. Smith, T. Misu, K. Fujihara, M. Bradl, H. Lassmann.
Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropath., 2010; 120:223-236. PM:20532539

K.J. Smith
Newly-lesioned tissue in MS - a role for oxidative damage? Brain, 2011;134:1877-1881. PM:21676995

The collaboration is multidisciplinary, including experimental neuropathology and microarray analysis, and examination of human MS brain tissue.</gtr:impact><gtr:partnerContribution>Our colleagues at the Medical University of Vienna provide histological examination of our experimental lesions, including microarray analysis. They are also valuable discussants in developing our ideas about the pathophysiology of MS.</gtr:partnerContribution><gtr:piContribution>Our group provides experimental tissue for examination.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>237878</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>A1270883-A3CF-49B2-B2F2-9EB5C45306B7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CTN Pre-clinical drug screening</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>9D61F9D5-4090-4C3B-833C-32760755AF5F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Research Trust Project Grant</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Brain Research Trust (BRT)</gtr:fundingOrg><gtr:id>A3678C3C-C461-425E-B376-A2FFC8BC3F0C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>194000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MS Society Project Grant</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>266B7F1D-3952-4537-9502-FD5B692157AA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>113203</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>7D587039-635E-4AA3-8C01-DEEF3A8D41B0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Merck Serono</gtr:department><gtr:description>Merck Serono</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Merck (KGaA)</gtr:fundingOrg><gtr:id>32714570-B925-4297-BC0A-F6AAD2B4FC82</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>214025</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>9254A7D5-D006-47E6-B5AA-4339FCD3B71D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Understanding how inflammation within the CNS can result in loss of function in diseases such as multiple sclerosis. Recognition of the role of energy insufficiency due to hypoxia, nitric oxide and superoxide.</gtr:description><gtr:id>E46ACC24-21C3-425C-AEC7-C489925D5B78</gtr:id><gtr:impact>Interest in participating in our research, and plans for two clinical trials.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Loss of function</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C380947-EDDA-4B39-B462-01E8CBC8E3E3"><gtr:id>5C380947-EDDA-4B39-B462-01E8CBC8E3E3</gtr:id><gtr:title>Newly lesioned tissue in multiple sclerosis--a role for oxidative damage?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbc394f2c999ae55bf9195e61fb2a23a"><gtr:id>fbc394f2c999ae55bf9195e61fb2a23a</gtr:id><gtr:otherNames>Smith KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A162457E-5693-4E92-A3F8-54E1DC37AF3D"><gtr:id>A162457E-5693-4E92-A3F8-54E1DC37AF3D</gtr:id><gtr:title>Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/368e34146c69fe2da37de4365d31ed10"><gtr:id>368e34146c69fe2da37de4365d31ed10</gtr:id><gtr:otherNames>Schuh C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A6973B6-06D0-41F4-A39C-D35701C3E35E"><gtr:id>0A6973B6-06D0-41F4-A39C-D35701C3E35E</gtr:id><gtr:title>Neuroprotection and repair in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d469ddfcd9562b3972ffe34f974f7d21"><gtr:id>d469ddfcd9562b3972ffe34f974f7d21</gtr:id><gtr:otherNames>Franklin RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74275E5A-8D88-4EA2-B239-831E92A1BEDA"><gtr:id>74275E5A-8D88-4EA2-B239-831E92A1BEDA</gtr:id><gtr:title>Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f01aee55e92ee99444433dc058e18197"><gtr:id>f01aee55e92ee99444433dc058e18197</gtr:id><gtr:otherNames>Sharma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65BBD6AD-5472-4AB9-81AB-5290B25EBC30"><gtr:id>65BBD6AD-5472-4AB9-81AB-5290B25EBC30</gtr:id><gtr:title>Origins of gliogenic stem cell populations within adult skin and bone marrow.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/38b70905c1f3a957902e8ffb9af75a31"><gtr:id>38b70905c1f3a957902e8ffb9af75a31</gtr:id><gtr:otherNames>Hunt DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA39B4D6-72CB-44E0-A491-96C73C887363"><gtr:id>CA39B4D6-72CB-44E0-A491-96C73C887363</gtr:id><gtr:title>The role of CD8(+) T cells in a model of multiple sclerosis induced with recombinant myelin oligodendrocyte glycoprotein.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76f470b9de1ef4c8355c84c83c595b04"><gtr:id>76f470b9de1ef4c8355c84c83c595b04</gtr:id><gtr:otherNames>Sajic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/881430B3-123C-4F2F-BC0A-0B0FF2DD44DE"><gtr:id>881430B3-123C-4F2F-BC0A-0B0FF2DD44DE</gtr:id><gtr:title>Neurological deficits caused by tissue hypoxia in neuroinflammatory disease.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dbce9497efbe264f7b2d2fc973fda7e"><gtr:id>3dbce9497efbe264f7b2d2fc973fda7e</gtr:id><gtr:otherNames>Davies AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0476BD38-C90A-4E3C-84ED-FA77406E3717"><gtr:id>0476BD38-C90A-4E3C-84ED-FA77406E3717</gtr:id><gtr:title>Axonal protection achieved by blockade of sodium/calcium exchange in a new model of ischemia in&amp;nbsp;vivo.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cec0ab85c50b0fe08657d72319d58e6b"><gtr:id>cec0ab85c50b0fe08657d72319d58e6b</gtr:id><gtr:otherNames>Bei F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3EA045C-320A-40C4-B7BD-77A1D6CA0D2D"><gtr:id>E3EA045C-320A-40C4-B7BD-77A1D6CA0D2D</gtr:id><gtr:title>Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76f470b9de1ef4c8355c84c83c595b04"><gtr:id>76f470b9de1ef4c8355c84c83c595b04</gtr:id><gtr:otherNames>Sajic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4867BE91-3BC1-4972-B545-EEE7CDAAA5E7"><gtr:id>4867BE91-3BC1-4972-B545-EEE7CDAAA5E7</gtr:id><gtr:title>Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a99bb4140a317a3b6051bf92775eadfe"><gtr:id>a99bb4140a317a3b6051bf92775eadfe</gtr:id><gtr:otherNames>Morsali D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAFE0C2F-DFC0-4D98-B677-A7E45D966105"><gtr:id>CAFE0C2F-DFC0-4D98-B677-A7E45D966105</gtr:id><gtr:title>Detection of cytochrome c oxidase activity and mitochondrial proteins in single cells.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d93bcd67cec2afab0839c2f0b6cf4528"><gtr:id>d93bcd67cec2afab0839c2f0b6cf4528</gtr:id><gtr:otherNames>Mahad DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79979CCF-A410-4126-893F-74CBE1609C85"><gtr:id>79979CCF-A410-4126-893F-74CBE1609C85</gtr:id><gtr:title>Lamotrigine monotherapy does not provide protection against the loss of optic nerve axons in a rat model of ocular hypertension.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d2a1cfb59235e7ed66e67e2290b933e"><gtr:id>1d2a1cfb59235e7ed66e67e2290b933e</gtr:id><gtr:otherNames>Marina N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800954</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>